Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASP Isotopes Inc.ASPI · Entity 5371 | Chief Financial Officer | July 01, 2026 | July 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASP Isotopes Inc.
Report date July 01, 2026 · Filed July 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,526,252 |
Reported balance
After 2026-07-01 transaction · row 1
1 source rowRow 1 · 2026-07-01 · Sale · Disposed 23,124 · Balance 1,526,252 F1: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 19, 2025 to cover tax withholding obligations in connection with the quarterly vesting of a restricted stock award. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.13 to $6.52, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 19, 2025 to cover tax withholding obligations in connection with the quarterly vesting of a restricted stock award.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.13 to $6.52, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 3, 2026 01:45 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 23,124 | $6.28 | $145,218.72 |
DisclosureSEC source: 0001477932-26-004177 · form4.xml · nonDerivative · entry 1 Kiessling Heather · CIK 0002026548 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,526,252 F1 · kind: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 19, 2025 to cover tax withholding obligations in connection with the quarterly vesting of a restricted stock award. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.13 to $6.52, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 28, 2026 Filed Jun 4, 2026 01:45 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 840,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-26-003630 · form4.xml · nonDerivative · entry 1 Kiessling Heather · CIK 0002026548 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,549,376 F1 · date: This award of common stock shall vest (subject to compliance with applicable vesting conditions) in semi-annual installments over a four-year period beginning on the grant date. F1 · price: This award of common stock shall vest (subject to compliance with applicable vesting conditions) in semi-annual installments over a four-year period beginning on the grant date. Read SEC document |
| April 15, 2026 Filed Apr 18, 2026 01:54 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 23,124 | $5.48 | $126,673.27 |
DisclosureSEC source: 0001477932-26-002388 · form4.xml · nonDerivative · entry 1 Kiessling Heather · CIK 0002026548 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 709,376 F1 · kind: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 19, 2025 to cover tax withholding obligations in connection with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.12 to $5.71, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2. Read SEC document |
| December 18, 2025 Filed Dec 30, 2025 02:30 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 80,000 | $5.80 | $463,840.00 |
DisclosureSEC source: 0001477932-25-009230 · form4.xml · nonDerivative · entry 1 Kiessling Heather · CIK 0002026548 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 732,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.73 to $5.885, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 1. Read SEC document |
| April 14, 2025 Filed Apr 15, 2025 12:42 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 400,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-25-002717 · form4.xml · nonDerivative · entry 1 Kiessling Heather · CIK 0002026548 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 812,500 F1 · date: This award of common stock shall vest (subject to compliance with applicable vesting conditions) in semi-annual installments over a four-year period beginning on the grant date. F1 · price: This award of common stock shall vest (subject to compliance with applicable vesting conditions) in semi-annual installments over a four-year period beginning on the grant date. Read SEC document |
| July 01, 2024 Filed Jul 1, 2024 20:21 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 400,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-24-004011 · form4.xml · nonDerivative · entry 1 Kiessling Heather · CIK 0002026548 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 412,500 F1 · date: This award of common stock was made in connection with the appointment of Ms. Kiessling as chief financial officer effective July 1, 2024, and shall vest (subject to compliance with applicable vesting conditions) in eight equal semi-annual installments over a four-year period beginning on the six-month anniversary of the grant date, as previously disclosed in the issuer's Form 8-K filed on June 13, 2024. F1 · price: This award of common stock was made in connection with the appointment of Ms. Kiessling as chief financial officer effective July 1, 2024, and shall vest (subject to compliance with applicable vesting conditions) in eight equal semi-annual installments over a four-year period beginning on the six-month anniversary of the grant date, as previously disclosed in the issuer's Form 8-K filed on June 13, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.